Open AccessClinical evaluation of Rasayana compound as an adjuvant in the management of tuberculosis with anti-Koch′s treatment
Author(s) -
Purvi Vyas,
HM Chandola,
Firoz Ghanchi,
Shivprakash Ranthem
Publication year - 2012
Publication title -
ayu
Language(s) - English
Resource type - Journals
eISSN - 0976-9382
pISSN - 0974-8520
DOI - 10.4103/0974-8520.100307
Subject(s) - traditional medicine , medicine , tinospora cordifolia , siddha , withania somnifera , echinacea (animal) , alternative medicine , pathology
Tuberculosis (TB) continues to intimidate the human race since time immemorial not only due to its effects as a medical malady, but also by its impact as a social and economic tragedy. At the dawn of the new millennium, we are still mute witnesses to the silent yet efficient march of this sagacious disease, its myriad manifestations and above all its unequalled, vicious power. Through the millennia, TB never ever disappeared from the developing world. In 1991, the World Health Assembly (WHA) resolution recognized TB as a major global public health problem. The DOTS strategy was launched in 1994, and became the global recommended strategy for TB control since then. The present study deals with clinical evaluation of Rasayana drugs considering of Amalaki (Emblica officinalis Gaertn.), Guduchi (Tinospora cordifolia willd.), Ashwagandha (Withania somnifera L.) Dunal, Yastimadhu (Glycyrrhiza glabra Linn.), Pippali (Piper longum Linn.), Sariva (Hemidesmus indicus R.Br.), Kustha (Saussurea lappa Falc.), Haridra (Curcuma longa Linn.) and Kulinjan (Alpinia galangal Linn.) as an adjuvant therapy with anti-Koch's treatment. The results obtained revealed that Rasayana compound was found to decrease cough (83%), fever (93%), dyspnea (71.3%), hemoptysis (87%) and increase body weight (7.7%) with statistically highly significant (P<0.001).